Key facts
- Optimus Pharma’s last known valuation is $338.7M (Sep 2022).
- It has raised $16.3M; the latest was PE Growth/Expansion in Apr 2026.
- Notable investors include Trans-Continental Capital Managers, Unichem Laboratories.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Optimus Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Optimus Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Optimus Pharma
Manufacturer of pharmaceutical products committed to providing and ensuring better healthcare across the globe. The company engages in the development, production, and delivery of pharmaceutical active ingredients and advanced drug intermediates for diabetes, cardiac, neurology, anti-bacterial, and anti-fungal therapies, thereby offering affordable products to its clients.
- Sector
- Healthcare
- HQ
- Hyderabad, India
- Founded
- 2004
- Employees
- 373
- Website
- optimuspharma.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Optimus Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Optimus Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Optimus Pharma in its N-PORT filings yet. We sweep new filings monthly.